Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Norbert-Claude GorinMyriam LabopinDidier BlaiseMarco de GrootGerard SociéJean Henri BourhisFabio CiceriEmmanuelle PolgeArnon NaglerMohamad MohtyPublished in: Cancer (2019)
In men who have intermediate-risk AML, allogenic transplantation from a sister MSD or a HAPLO donor produces similar GRFS. However, in men who have high-risk AML, a HAPLO donor combined with prophylactic high-dose cyclophosphamide posttransplantation may be a better choice.